Weeks after getting off a major $110 million series B round, well-funded Passage Bio has grabbed a new C-suite member on top of its cash haul.
The deal gives Clovis the ex-Europe rights to a cancer candidate set to enter the clinic in the second half of next year.
Sethi spent the past four years at AstraZeneca, rising to the post of chief physician scientist at its clinical discovery unit.
Contract research organization PPD is expanding its Richmond, Virginia, lab by adding 200 new staffers and boosting its research capabilities.
The IPO window is still wide open for biotech, and French Big Pharma-partnered Innate is looking to jump right on through.
Omega Therapeutics is working on treatments that adjust gene expression up or down without making permanent changes to the genome.
Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.
Alexion replaces CFO Clancy in possible M&A push; Black Diamond nabs three new R&D execs; X4 Pharma founder Skerlj takes on R&D head duties.
Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.
The RV144 HIV vaccine regimen containing clades B and E inserts produced strong immune responses in South Africa, where clade C dominates.
